Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/28257
Title: Dilated thin-walled blood and lymphatic vessels in human endometrium: A potential role for VEGF-D in progestin-induced break-through bleeding.
Authors: Fu L.;Rogers P.A.W.;Cann L.M.;Dimitriadis E.;Girling J.E.;Donoghue J.F.;McGavigan C.J.;Lederman F.L.
Institution: (Donoghue, McGavigan) Centre for Women's Health Research, Department of Obstetrics and Gynaecology and Monash Institute for Medical Research, Monash University, Clayton, VIC, Australia (Lederman, Cann, Fu, Girling, Rogers) Gynaecology Research Centre, Department of Obstetrics and Gynaecology, The University of Melbourne, Royal Women's Hospital, Melbourne, VIC, Australia (Dimitriadis) Embryo Implantation Laboratory, Prince Henry's Institute for Medical Research, Monash Medical Centre, Clayton, VIC, Australia (Donoghue) Oncogenic Signalling Laboratory, Monash Institute for Medical Research, Monash University, Clayton, VIC, Australia (McGavigan) Department of Obstetrics and Gynaecology, Flinders Medical Centre, Bedford Park, SA, Australia
Issue Date: 5-Mar-2012
Copyright year: 2012
Publisher: Public Library of Science (185 Berry Street, Suite 1300, San Francisco CA 94107, United States)
Place of publication: United States
Publication information: PLoS ONE. 7 (2) (no pagination), 2012. Article Number: e30916. Date of Publication: 17 Feb 2012.
Abstract: Progestins provide safe, effective and cheap options for contraception as well as the treatment of a variety of gynaecological disorders. Episodes of irregular endometrial bleeding or breakthrough bleeding (BTB) are a major unwanted side effect of progestin treatment, such that BTB is the leading cause for discontinued use of an otherwise effective and popular medication. The cellular mechanisms leading to BTB are poorly understood. In this study, we make the novel finding that the large, dilated, thin walled vessels characteristic of human progestin-treated endometrium include both blood and lymphatic vessels. Increased blood and lymphatic vessel diameter are features of VEGF-D action in other tissues and we show by immunolocalisation and Western blotting that stromal cell decidualisation results in a significant increase in VEGF-D protein production, particularly of the proteolytically processed 21 kD form. Using a NOD/scid mouse model with xenografted human endometrium we were able to show that progestin treatment causes decidualisation, VEGF-D production and endometrial vessel dilation. Our results lead to a novel hypothesis to explain BTB, with stromal cell decidualisation rather than progestin treatment per se being the proposed causative event, and VEGF-D being the proposed effector agent. © 2012 Donoghue et al.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1371/journal.pone.0030916
PubMed URL: 22383980 [http://www.ncbi.nlm.nih.gov/pubmed/?term=22383980]
ISSN: 1932-6203 (electronic)
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/28257
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

42
checked on Aug 16, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.